

Blueteq is not just about cost, it's an opportunity to optimise antiretroviral therapy

Sinead Peare

Guys and St Thomas' NHS Foundation Trust, UK

Blueteq is not just about cost, it's an opportunity to optimise antiretroviral therapy

Sinéad Peare – Clinical Pharmacist (Long term Conditions – HIV)
Guys and St Thomas' NHS Foundation Trust

No Conflict of Interest



**What is Blueteq,
and why do we
use it?**



165 people
(76%)
remain on
Symtuza

410 people
(61%)
remain on
current
treatment

The most common
reasons for
remaining on
treatment were
patient preference,
the need for single
tablet regimen or
adherence

As of 1st Dec 2022
822 people identified
↓
677 people reviewed

£42,000 per
month saved
in drug costs

267 people
(39%)
switched
treatment

73 people (27%)
switched to more
expensive regimens.
This was most
commonly seen in
people taking Eviplera
(47 people - 44%)

95 people switched
off a boosted PI all
together, most
commonly from
those originally
taking Evotaz or
Rezolsta

103 people
(39%) who
switched
treatments
switched to
an STR



Conclusions



Despite 27% of people switching to more expensive regimens, £42,000 per month has been saved





Single tablet regimens and adherence along with people's preference were the main reason for treatment choices

Symtuza

61% of people remained on current regimens, but 76% of people taking Symtuza remained on Symtuza



 Sinead_Peare

 Sinead.peare@nhs.net